VentriNova is revolutionizing cardiac regenerative medicine by reversing cardiac damage pharmacologically. With no cure available and unlike current exogenous repair approaches (stem cells, skeletal myoblasts), VentriNova’s pioneering approach of cyclin A2 modulation stimulates endogenous growth of new myocytes (heart muscle cells). Therapeutic regeneration of myocytes has been significantly demonstrated in small animals and in a large animal model of porcine myocardial infarction.

VN-100, Gene Therapy

The Company’s lead product, is viral vector-based gene therapy that induces cardiomyocyte division in adult heart tissue by delivery of the cyclin A2 gene – the principal gene regulating cell cycle activity. VN-100 has been tested extensively in small and large animal models and has been shown to significantly improve ejection fraction along with clear evidence of cellular regeneration via cardiomyocyte mitotic division.

VentriNova is now poised to request investigational new drug approval from the FDA, and seeks to complete toxicity testing and verify the proof-of concept data obtained in large animals with GLP-compliant delivery systems over the next 18 months. VentriNova is pursuing parallel paths of testing the delivery of forms of cyclin A2 in large animals and the identification of a biologic/small molecule to activate the endogenous cyclin A2 gene in order to achieve the same effect.

The Science

Dr. Chaudhry’s seminal publication (Journal of Biological Chemistry, August 2004) demonstrated for the first time that mitosis in postnatal cardiomyocytes in the mouse heart could be achieved by continuously expressing cyclin A2, a gene that is normally silenced in mammalian hearts after birth. When these mouse hearts were subjected to myocardial infarction, new myocytes grew in the infarcted areas and restored cardiac function in a dramatic way when compared to control mice.

These results have been published in Circulation Research and made the cover of the June 22, 2007 issue. Furthermore, when delivered exogenously via viral vector to genetically naive rat hearts after myocardial infarction, cyclin A2 conferred significant enhancement of cardiac function with cellular regeneration of cardiomyocytes. These results were published in Circulation in 2006. These studies have been confirmed using viral delivery of cyclin A2 in the porcine model of myocardial infarction, and a manuscript describing these results is in submission

Growing International Patent Portfolio

VentriNova’s founder and her colleagues developed the patented technology to utilize the heart’s intrinsic cell division machinery to grow new heart muscle cells after myocardial infarction. This results in a very significant recovery of cardiac contractile function in both small and large animal models. VentriNova holds the license to this technology as the foundation of its expanding international patent portfolio.

VentriNova’s intellectual property is protected via the following:

  • Scientific knowledge- over 12 years of pre-clinical research at Columbia University and Mount Sinai School of Medicine has resulted in a therapeutic strategy that produces unparalleled results across multiple animal models at both the cellular and whole organ level with regards to cardiac regeneration.
  • Proprietary use of cyclin A2-driven endogenous side-population stem cells to aid in the cardiac regenerative process
    Rigorous understanding of the cellular and molecular mechanisms involved in cardiac regeneration.
  • Cutting edge advances in modulating gene expression via epigenetic mechanisms.
  • Academic credentials of and growing list of publications by VentriNova’s scientific founder Hina W. Chaudhry, MD in leading scientific journals.